TNFSF13B Specific Neutra™ Antibody Products
Product listTNFSF13B (TNF Superfamily Member 13b), also known as BAFF (B-cell Activating Factor) or CD257, is a cytokine that plays a vital role in the immune system. Creative Biolabs provides comprehensive and in-depth information about TNFSF13B to help clients better understand the characteristics and potential applications of this key target.
Main Signaling Pathways Involved in TNFSF13B
TNFSF13B, widely expressed in various cell types such as monocytes, dendritic cells, and bone marrow stromal cells, plays a core role in the survival, proliferation, and differentiation of B cells. It also activates T cells, promoting their proliferation and differentiation, thus demonstrating multiple influences in immune regulation. TNFSF13B engages with three principal receptors — B-cell Activating Factor Receptor (BAFF-R), Transmembrane Activator and Calcium Modulator-Cyclophilin Ligand Interactor (TACI), and B-cell Maturation Antigen (BCMA) — initiating critical signaling cascades such as NF-κB, PI3K/Akt, and MAPK. These pathways play a pivotal role in diverse cellular processes and immunological functions.
Fig.1 Expression of BAFFR, TACI and BCMA in B cell development.1
Abnormal Expression of TNFSF13B and Autoimmune Diseases
The dysregulation of TNFSF13B expression is intricately linked to the development of a variety of human autoimmune disorders.
- Systemic Lupus Erythematosus (SLE): In SLE patients, increased expression levels of TNFSF13B are associated with excessive activation of B cells and production of autoantibodies.
- Multiple Sclerosis (MS): Studies have found that the level of TNFSF13B expression products is also increased in the serum of MS patients, suggesting its potential role in the disease's pathogenesis.
- IgA Nephropathy: Elevated expression of TNFSF13B is associated with abnormal B cell responses in IgA Nephropathy.
- Sjögren's Syndrome: In this disease, increased expression of TNFSF13B is related to glandular dysfunction and hyperactivity of the immune system.
- Rheumatoid Arthritis: High levels of TNFSF13B expression in patients with rheumatoid arthritis are associated with joint inflammation, joint damage, and pain.
These findings reveal the significant role of TNFSF13B in the development of autoimmune diseases, especially in promoting the survival and function of pathological B cells.
Therapeutic Strategies Targeting TNFSF13B
In clinical medicine, TNFSF13B has been proven to be a potential therapeutic target, and antibody drugs targeting it have been used to treat autoimmune diseases such as SLE and rheumatoid arthritis.
- Drug Development: The development of drugs targeting TNFSF13B, such as anti-TNFSF13B antibodies, has been proven effective in treating diseases like SLE and rheumatoid arthritis.
- Mechanism of Action: These drugs work by targeting and neutralizing TNFSF13B, reducing the overactivation of B cells and production of autoantibodies, thereby alleviating symptoms and controlling disease progression.
- Clinical Applications: Anti-TNFSF13B antibody drugs have been approved for use in treating SLE in several countries, and their effectiveness in improving patient symptoms and quality of life has been clinically confirmed.
Supply and Custom Development of Anti-TNFSF13B Antibodies
In the future medical field, we have reason to believe that more precise anti-TNFSF13B antibody drugs will become a new direction in research targeting TNFSF13B. This is because antibody drugs targeting TNFSF13B not only offer more effective treatment options but also significantly reduce potential side effects. To support the development of this research field, Creative Biolabs provides a complete set of high-quality antibody products and customized services targeting TNFSF13B, aimed at assisting and accelerating the research progress of scientists in this field. For more information about our products or to discuss your specific requirements, don't hesitate to contact us.
REFERENCE
- Smulski, CR.; Eibel, H. BAFF and BAFF-receptor in B Cell selection and survival. Frontiers in Immunology. 2018, 9:2285.
